Adaptimmune Therapeutics plc., a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, will locate its U.S. headquarters and clinical operations in a newly developed facility to be constructed at The Navy Yard in Philadelphia, PA. The 47,400 square foot facility, located at 351 Rouse Boulevard in The Navy Yard’s Corporate Center, will house a state-of-the-art cGMP manufacturing facility designed to support the clinical development and initial commercializ...